Dr Shravan Subramanyam to Head Claypond Capital's Medtech Platform

Founded by Ranjan Pai, a prominent figure in the Manipal Education and Medical Group, Claypond Capital operates as a family investment office, primarily focusing on investments in startups and emerging companies

Bengaluru-based investment firm Claypond Capital has appointed Dr Shravan Subramanyam to head its medical technology platform.

The platform aims to enhance medical equipment and digital solutions, targeting both domestic and international markets with a focus on localization and innovation.

Founded by Ranjan Pai, a prominent figure in the Manipal Education and Medical Group, Claypond Capital operates as a family investment office, primarily focusing on investments in startups and emerging companies

Dr Subramanyam, an alumnus of Madras Medical College and Cornell University, brings two decades of experience in life sciences and medical devices. His previous roles include leadership positions at Roche and Novartis, and he has also served as president of NATHEALTH and co-chaired medical technology committees for FICCI and CII.

Expressing enthusiasm, Dr Subramanyam said, “The next decade holds a lot of promise for medical innovation and integration of various technologies, particularly digital solutions. I look forward to working closely with med-tech companies on behalf of Claypond, to scale up their presence in South Asia and overseas.”

Dr Ranjan Pai emphasized the evolving nature of healthcare delivery in a post-COVID-19 world.

He stated, “Healthcare delivery is changing profoundly in the post-Covid world, and medical technology has a big role to play in making healthcare accessible and affordable. Innovation will require long-term capital and collaboration between industry and academia. We believe the platform approach will address the opportunity for India to participate in the growth of the med-tech sector across regions.”

Reportedly, the market, valued at INR 1.2 lakh Cr in FY24, is projected to grow at a compound annual growth rate of 11% until FY32. With 80% of devices currently imported, there is significant potential for import substitution.

Factors such as increased insurance coverage, rising incomes, expanding healthcare infrastructure in smaller cities, the prevalence of chronic diseases, and government incentives are expected to drive the sector's growth.

Dr Subramanyam aims to drive strategy and execution for Claypond Capital’s medtech platform, focusing on innovation: Integrating various technologies, particularly digital solutions, to enhance medical innovation. It will also develop localized medical equipment to reduce dependency on imports. Further, the firm aims to make healthcare more accessible and affordable, especially in the post-COVID world.

Claypond Capital invests in various sectors, including healthcare, education, e-commerce, aviation, etc. The firm supports innovative medical technology and digital healthcare solutions, invests in edtech companies like Byju's and Aakash, backs online platforms such as PharmEasy and FirstCry, among other initiatives.

The investment arm of Dr Ranjan Pai, has recently partnered with Premji Invest to invest approximately $125 million in Akasa Air to support its expansion plans

Claypond Capital’s platform approach aims to seize these opportunities, fostering the development of the medtech industry in India and globally.

Stay tuned for more such updates on Digital Health News.